Cargando…

Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes

Young women’s breast cancer (YWBC) has poor prognosis and known interactions with parity. Women diagnosed within 5–10 years of childbirth, defined as postpartum breast cancer (PPBC), have poorer prognosis compared to age, stage, and biologic subtype-matched nulliparous patients. Genomic differences...

Descripción completa

Detalles Bibliográficos
Autores principales: Jindal, Sonali, Pennock, Nathan D., Sun, Duanchen, Horton, Wesley, Ozaki, Michelle K., Narasimhan, Jayasri, Bartlett, Alexandra Q., Weinmann, Sheila, Goss, Paul E., Borges, Virginia F., Xia, Zheng, Schedin, Pepper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566602/
https://www.ncbi.nlm.nih.gov/pubmed/34732713
http://dx.doi.org/10.1038/s41467-021-26505-3
_version_ 1784594051442409472
author Jindal, Sonali
Pennock, Nathan D.
Sun, Duanchen
Horton, Wesley
Ozaki, Michelle K.
Narasimhan, Jayasri
Bartlett, Alexandra Q.
Weinmann, Sheila
Goss, Paul E.
Borges, Virginia F.
Xia, Zheng
Schedin, Pepper
author_facet Jindal, Sonali
Pennock, Nathan D.
Sun, Duanchen
Horton, Wesley
Ozaki, Michelle K.
Narasimhan, Jayasri
Bartlett, Alexandra Q.
Weinmann, Sheila
Goss, Paul E.
Borges, Virginia F.
Xia, Zheng
Schedin, Pepper
author_sort Jindal, Sonali
collection PubMed
description Young women’s breast cancer (YWBC) has poor prognosis and known interactions with parity. Women diagnosed within 5–10 years of childbirth, defined as postpartum breast cancer (PPBC), have poorer prognosis compared to age, stage, and biologic subtype-matched nulliparous patients. Genomic differences that explain this poor prognosis remain unknown. In this study, using RNA expression data from clinically matched estrogen receptor positive (ER+) cases (n = 16), we observe that ER+ YWBC can be differentiated based on a postpartum or nulliparous diagnosis. The gene expression signatures of PPBC are consistent with increased cell cycle, T-cell activation and reduced estrogen receptor and TP53 signaling. When applied to a large YWBC cohort, these signatures for ER+ PPBC associate with significantly reduced 15-year survival rates in high compared to low expressing cases. Cumulatively these results provide evidence that PPBC is a unique entity within YWBC with poor prognostic phenotypes.
format Online
Article
Text
id pubmed-8566602
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-85666022021-11-15 Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes Jindal, Sonali Pennock, Nathan D. Sun, Duanchen Horton, Wesley Ozaki, Michelle K. Narasimhan, Jayasri Bartlett, Alexandra Q. Weinmann, Sheila Goss, Paul E. Borges, Virginia F. Xia, Zheng Schedin, Pepper Nat Commun Article Young women’s breast cancer (YWBC) has poor prognosis and known interactions with parity. Women diagnosed within 5–10 years of childbirth, defined as postpartum breast cancer (PPBC), have poorer prognosis compared to age, stage, and biologic subtype-matched nulliparous patients. Genomic differences that explain this poor prognosis remain unknown. In this study, using RNA expression data from clinically matched estrogen receptor positive (ER+) cases (n = 16), we observe that ER+ YWBC can be differentiated based on a postpartum or nulliparous diagnosis. The gene expression signatures of PPBC are consistent with increased cell cycle, T-cell activation and reduced estrogen receptor and TP53 signaling. When applied to a large YWBC cohort, these signatures for ER+ PPBC associate with significantly reduced 15-year survival rates in high compared to low expressing cases. Cumulatively these results provide evidence that PPBC is a unique entity within YWBC with poor prognostic phenotypes. Nature Publishing Group UK 2021-11-03 /pmc/articles/PMC8566602/ /pubmed/34732713 http://dx.doi.org/10.1038/s41467-021-26505-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Jindal, Sonali
Pennock, Nathan D.
Sun, Duanchen
Horton, Wesley
Ozaki, Michelle K.
Narasimhan, Jayasri
Bartlett, Alexandra Q.
Weinmann, Sheila
Goss, Paul E.
Borges, Virginia F.
Xia, Zheng
Schedin, Pepper
Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes
title Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes
title_full Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes
title_fullStr Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes
title_full_unstemmed Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes
title_short Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes
title_sort postpartum breast cancer has a distinct molecular profile that predicts poor outcomes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566602/
https://www.ncbi.nlm.nih.gov/pubmed/34732713
http://dx.doi.org/10.1038/s41467-021-26505-3
work_keys_str_mv AT jindalsonali postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes
AT pennocknathand postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes
AT sunduanchen postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes
AT hortonwesley postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes
AT ozakimichellek postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes
AT narasimhanjayasri postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes
AT bartlettalexandraq postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes
AT weinmannsheila postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes
AT gosspaule postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes
AT borgesvirginiaf postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes
AT xiazheng postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes
AT schedinpepper postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes